TLDC2

Across TCGA pan-cancer cohorts, TLDC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TLDC2 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TLDC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TLDC2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, OV, and COAD are the cancer types where TLDC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.632	0.891	<.001	54	view →
OV	DFS	Tertile	All	0.535	0.896	.045	8	view →
COAD	DFS	Median	III,IV	0.848	1.000	.049	6	view →
GBM	OS	Quartile	All	0.750	0.903	.008	5	view →
LSCC	DFS	Tertile	All	0.941	0.249	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TLDC2–PDAC (DFS)

Open the PDAC breakdown →